All patients
Age < 65y (younger) Age > 65y Asian type cell type, adenocarcinoma cell ECOG 0 ECOG 1 EGFR mutant EGFR mutation Ex19del EGFR mutation L858R EGFR wild type Gender, female Gender, male RAS mutant RAS wild type smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
lung cancer : non small cell (NSCLC), ... vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results A7471028, 2012 0.80 [0.56; 1.14]
ARCHER 1009 (all population), 2014 1.08 [0.91; 1.27]
ARCHER 1009 (KRAS wild type), 2014 1.10 [0.88; 1.36]
ARCHER 1050, 2017 0.76 [0.58; 0.99]
NCIC CTG BR.26, 2014 1.00 [0.83; 1.21]
0.97 [0.85 ; 1.11 ] A7471028, 2012, ARCHER 1009 (all population), 2014, ARCHER 1009 (KRAS wild type), 2014, ARCHER 1050, 2017, NCIC CTG BR.26, 2014 5 43% 2,757 low not evaluable deaths (OS) (extension)detailed results ARCHER 1050, 2017 0.75 [0.59; 0.95]
0.75 [0.59 ; 0.95 ] ARCHER 1050, 2017 1 0% 452 NA not evaluable progression or deaths (PFS)detailed results A7471028, 2012 0.66 [0.47; 0.92]
ARCHER 1009 (all population), 2014 0.94 [0.80; 1.10]
ARCHER 1009 (KRAS wild type), 2014 1.02 [0.83; 1.25]
ARCHER 1050, 2017 0.59 [0.47; 0.74]
NCIC CTG BR.26, 2014 0.66 [0.55; 0.79]
0.76 [0.61 ; 0.95 ] A7471028, 2012, ARCHER 1009 (all population), 2014, ARCHER 1009 (KRAS wild type), 2014, ARCHER 1050, 2017, NCIC CTG BR.26, 2014 5 82% 2,757 low not evaluable objective responses (ORR)detailed results A7471028, 2012 3.65 [1.28; 10.43]
ARCHER 1009 (all population), 2014 1.44 [0.92; 2.26]
ARCHER 1009 (KRAS wild type), 2014 1.19 [0.70; 2.03]
ARCHER 1050, 2017 0.53 [0.33; 0.85]
NCIC CTG BR.26, 2014 6.02 [1.83; 19.81]
1.57 [0.79 ; 3.13 ] A7471028, 2012, ARCHER 1009 (all population), 2014, ARCHER 1009 (KRAS wild type), 2014, ARCHER 1050, 2017, NCIC CTG BR.26, 2014 5 83% 2,757 low not evaluable AE (any grade)detailed results ARCHER 1050, 2017 4.11 [0.46; 37.05]
4.11 [0.46 ; 37.05 ] ARCHER 1050, 2017 1 0% 451 NA not evaluable AE (grade 3-4)detailed results ARCHER 1050, 2017 2.41 [1.64; 3.53]
2.41 [1.64 ; 3.53 ] ARCHER 1050, 2017 1 0% 451 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results ARCHER 1050, 2017 1.61 [0.95; 2.72]
NCIC CTG BR.26, 2014 11.74 [2.82; 48.89]
3.87 [0.56 ; 26.81 ] ARCHER 1050, 2017, NCIC CTG BR.26, 2014 2 85% 1,167 low not evaluable SAE (any grade)detailed results NCIC CTG BR.26, 2014 1.13 [0.82; 1.56]
1.13 [0.82 ; 1.56 ] NCIC CTG BR.26, 2014 1 0% 716 NA not evaluable TRAE (any grade)detailed results ARCHER 1009 (all population), 2014 1.77 [1.07; 2.93]
1.77 [1.07 ; 2.93 ] ARCHER 1009 (all population), 2014 1 0% 872 NA not evaluable TRAE (grade 3-4)detailed results ARCHER 1009 (all population), 2014 1.68 [1.23; 2.28]
1.68 [1.23 ; 2.28 ] ARCHER 1009 (all population), 2014 1 0% 872 NA not evaluable TRAE leading to death (grade 5)detailed results A7471028, 2012 1.01 [0.14; 7.33]
ARCHER 1009 (all population), 2014 4.03 [0.45; 36.18]
NCIC CTG BR.26, 2014 3.02 [0.15; 60.52]
2.06 [0.55 ; 7.72 ] A7471028, 2012, ARCHER 1009 (all population), 2014, NCIC CTG BR.26, 2014 3 0% 1,775 low not evaluable TRAE leading to discontinuation (any grade)detailed results A7471028, 2012 3.74 [0.76; 18.52]
ARCHER 1050, 2017 1.50 [0.75; 2.96]
1.76 [0.89 ; 3.50 ] A7471028, 2012, ARCHER 1050, 2017 2 7% 638 low not evaluable 0.5 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-03 19:43 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334
- treatments: 427
